Sanofi-aventis doubles syringe production capacity and diversifies vaccine production at the Le Trait Manufacturing Plant
The Le Trait manufacturing site specializes in producing high-tech sterile injectable products, primarily for export. Over the past 40 years, the site has invested in the most innovative technologies in order to meet patients’ needs and requirements of various international markets, in particular the United States and Japan. The investment in these new production units, one of the largest made on this site since its creation, represents 87 million euros over the past three years.
“Le Trait is one of many examples of sanofi-aventis’ desire to invest in France in order to be able to meet worldwide public health challenges,” said sanofi-aventis Chief Executive Officer Christopher A. Viehbacher. “A cutting-edge technological platform, the Le Trait site produces one million syringes a day and exports close to 90% of its production, 25% of which for the North American market.”
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.